1. Aldafermin in patients with non-alcoholic steatohepatitis (ALPINE 2/3): a randomised, double-blind, placebo-controlled, phase 2b trial. (July 2022) Authors: Harrison, Stephen A; Abdelmalek, Manal F; Neff, Guy; Gunn, Nadege; Guy, Cynthia D; Alkhouri, Naim; Bashir, Mustafa R; Freilich, Bradley; Kohli, Anita; Khazanchi, Arun; Sheikh, Muhammad Y; Leibowitz, Mark; Rinella, Mary E; Siddiqui, Mohammad S; Kipnes, Mark; Moussa, Sam E; Younes, Ziad H; Bansal, ... Journal: Lancet gastroenterology and hepatology Issue: Volume 7:Number 7(2022) Page Start: 603 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. Emtricitabine and tenofovir alafenamide vs emtricitabine and tenofovir disoproxil fumarate for HIV pre-exposure prophylaxis (DISCOVER): primary results from a randomised, double-blind, multicentre, active-controlled, phase 3, non-inferiority trial. Issue 10246 (25th July 2020) Authors: Mayer, Kenneth H; Molina, Jean-Michel; Thompson, Melanie A; Anderson, Peter L; Mounzer, Karam C; De Wet, Joss J; DeJesus, Edwin; Jessen, Heiko; Grant, Robert M; Ruane, Peter J; Wong, Pamela; Ebrahimi, Ramin; Zhong, Lijie; Mathias, Anita; Callebaut, Christian; Collins, Sean E; Das, Moupali; McCall... Journal: Lancet Issue: Volume 396:Issue 10246(2020) Page Start: 239 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. Long-term safety and efficacy of emtricitabine and tenofovir alafenamide vs emtricitabine and tenofovir disoproxil fumarate for HIV-1 pre-exposure prophylaxis: week 96 results from a randomised, double-blind, placebo-controlled, phase 3 trial. Issue 7 (July 2021) Authors: Ogbuagu, Onyema; Ruane, Peter J; Podzamczer, Daniel; Salazar, Laura C; Henry, Keith; Asmuth, David M; Wohl, David; Gilson, Richard; Shao, Yongwu; Ebrahimi, Ramin; Cox, Stephanie; Kintu, Alexander; Carter, Christoph; Das, Moupali; Baeten, Jared M; Brainard, Diana M; Whitlock, Gary; Brunetta, Jason... Journal: Lancet Issue: Volume 8:Issue 7(2021) Page Start: e397 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
4. Safety and efficacy of a fixed-dose combination regimen of grazoprevir, ruzasvir, and uprifosbuvir with or without ribavirin in participants with and without cirrhosis with chronic hepatitis C virus genotype 1, 2, or 3 infection (C-CREST-1 and C-CREST-2, part B): two randomised, phase 2, open-label trials. (November 2017) Authors: Lawitz, Eric; Buti, Maria; Vierling, John M; Almasio, Piero L; Bruno, Savino; Ruane, Peter J; Hassanein, Tarek I; Muellhaupt, Beat; Pearlman, Brian; Jancoriene, Ligita; Gao, Wei; Huang, Hsueh-Cheng; Shepherd, Aimee; Tannenbaum, Brynne; Fernsler, Doreen; Li, Jerry J; Grandhi, Anjana; Liu, Hong; Su... Journal: Lancet gastroenterology and hepatology Issue: Volume 2:Number 11(2017) Page Start: 814 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗